AtriCure (AtriCure) Capital Expenditure

: $-42.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

AtriCure's cash flow for capital expenditures for the three months ended in Dec. 2023 was $-2.8 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $-42.00 Mil.

AtriCure Capital Expenditure Historical Data

The historical data trend for AtriCure's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

-12.18

-5.26

-9.75

-16.88

-42.00

AtriCure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capital Expenditure																-4.17	-2.50	-33.08	-3.63	-2.79

AtriCure Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.00 Mil.

AtriCure (AtriCure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

7555 Innovation Way, Mason, OH, USA, 45040

Website

https://www.atricure.com

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Executives

Karl S. Dahlquist	officer: Chief Legal Officer	7555 INNOVATION WAY, MASON OH 45040
Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy	officer: Chief Scientific Officer	7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Tonya Austin	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick	officer: Chief Financial Officer	7555 INNOVATION WAY, MASON OH 45040
Mark A Collar	director	382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith	officer: SVP of Sales and Marketing	7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera	officer: VP; Product Development	7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky	officer: SVP, Mktg & Business Develop	7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake	director	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein	director